




RealRate

PHARMACEUTICAL 2014

Cytokinetics INC
Rank 109 of 234



Cytokinetics



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Cytokinetics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cytokinetics INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 38% points. The greatest weakness of Cytokinetics INC is the variable Research and Development, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 269%, being 26% points above the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	79,338
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	26,704
Liabilities, Non-Current	0
Other Assets	2,629
Other Compr. Net Income	-11
Other Expenses	0
Other Liabilities	2,042
Other Net Income	177
Other Revenues	30,648
Property and Equipment	1,221
Research and Development	49,450
Selling, General and Administrative Expense	15,092

Output Variable	Value in 1000 USD
Assets	83,188
Liabilities	28,746
Expenses	64,542
Revenues	30,648
Stockholders Equity	54,442
Net Income	-33,717
Comprehensive Net Income	-33,722
BaseVar	103,656
ECR before LimitedLiability	152%
Economic Capital Ratio	269%